Summary of Key Findings Oxygenation and Respiratory Outcomes: Hydrocortisone significantly improved oxygenation (PaO₂/FiO₂ ratio) and increased the number of mechanical ventilation-free days. This suggests that hydrocortisone could be beneficial in enhancing respiratory outcomes. Reduction in Major Complications: There was a notable reduction in the incidence of major complications, including delayed septic shock and MODS, among patients treated with hydrocortisone. Mortality: ICU, hospital, and 60-day mortality were significantly lower in the hydrocortisone group, indicating a potential survival benefit. Length of Stay and Ventilation Duration: Patients in the hydrocortisone group had shorter ICU stays, hospital stays, and duration on mechanical ventilation, supporting its efficacy in reducing the burden of intensive care needs. Safety Profile: Although complications like ARDS, ventilator-associated pneumonia, and acute renal failure were monitored, there were no significant increases in these adverse events with hydrocortisone. This supports its safety profile in the ICU setting.
[1][2][3][4][5] Table1. Common Variables and Results Across [6], Nafae 2013, and Cape Cod 2023.
Parameter/Outcome | Placebo | Hydrocortisone | p-Value | Interpretation |
---|---|---|---|---|
Demographics | ||||
Male/Female | 15/8 | 17/6 | 0.53 | No significant difference in gender distribution |
Age, years | 66.6 ± 14.7 | 60.4 ± 17.3 | 0.20 | No significant age difference |
Smoking Habit | See subgroup analysis | See subgroup analysis | NS | Not significantly different |
Severity Scores | ||||
APACHE II Score | 18.2 ± 4.0 | 17.2 ± 4.1 | 0.39 | No significant difference in severity |
MODS Score | 1.2 ± 0.4 | 1.2 ± 0.5 | 0.75 | No significant difference |
Vital Signs and Laboratory Values | ||||
Temperature (°C) | 38.2 ± 1.2 | 38.3 ± 0.9 | 0.76 | No significant difference |
WBC Count (×10⁹/L) | 13.9 ± 5.1 | 13.4 ± 5.5 | 0.73 | No significant difference |
PaO₂/FiO₂ Ratio | 178 ± 58 | 141 ± 49 | 0.03 | Significant difference; lower in hydrocortisone group |
PaO₂/FiO₂ ≤ 200 | 13 (57%) | 21 (91%) | 0.02 | Significant; worse oxygenation in hydrocortisone group |
CRP (mg/dL) | 29 (6–200) | 55 (14–349) | 0.04 | Significant; higher CRP in hydrocortisone group |
Respiratory Support and Ventilation | ||||
On Mechanical Ventilation | 19 (83%) | 15 (65%) | 0.18 | Not significant |
Mechanical Ventilation-Free Days | 0 (0–6) | 4 (0–7) | 0.01 | Significant; more vent-free days in hydrocortisone |
PaO₂/FiO₂ Ratio (after treatment) | 237 ± 92 | 332 ± 80 | 0.0008 | Significant improvement with hydrocortisone |
PaO₂/FiO₂ Improvement ≥ 100 | 8 (35%) | 20 (87%) | 0.0007 | Significant improvement in oxygenation |
Chest Radiograph and MODS | ||||
Chest Radiograph Score | 2.6 ± 1.3 | 1.1 ± 0.7 | < 0.0001 | Significant improvement with hydrocortisone |
Improvement in Chest Radiograph Score | 5 (22%) | 21 (91%) | < 0.0001 | Significant improvement with hydrocortisone |
Patients with MODS | 16 (70%) | 8 (35%) | 0.02 | Significant reduction in MODS with hydrocortisone |
Shock and Complications | ||||
Delayed Septic Shock by Day 8 | 9 (43%) | 0 (0%) | 0.001 | Significant reduction in delayed septic shock |
New ARDS by Day 8 | 3 (13%) | 0 (0%) | 0.23 | Not significant |
Major Complications | ||||
Major Complications | 18 (78%) | 6 (26%) | < 0.001 | Significant reduction in complications |
Delayed Septic Shock | 10 (52%) | 0 (0%) | < 0.001 | Significant reduction with hydrocortisone |
Shock Not Related to Sepsis | 2 (9%) | 0 (0%) | 0.5 | Not significant |
ARDS | 4 (17%) | 0 (0%) | 0.11 | Not significant |
Nosocomial Infection | 4 (18%) | 0 (0%) | 0.11 | Not significant |
Ventilator-Associated Pneumonia | 3 (13%) | 0 (0%) | 0.23 | Not significant |
Acute Renal Failure | 3 (13%) | 0 (0%) | 0.23 | Not significant |
Mortality and Survival | ||||
ICU Mortality | 7 (30%) | 0 (0%) | 0.009 | Significant reduction in ICU mortality |
Hospital Mortality | 7 (30%) | 0 (0%) | 0.009 | Significant reduction in hospital mortality |
60-day Mortality | 8 (38%) | 0 (0%) | 0.001 | Significant reduction in 60-day mortality |
Length of Stay and Mechanical Ventilation | ||||
Length of ICU Stay, days | 18 (3–45) | 10 (4–33) | 0.01 | Significant reduction in ICU stay |
Length of Hospital Stay, days | 21 (3–72) | 13 (10–53) | 0.03 | Significant reduction in hospital stay |
Duration of Mechanical Ventilation, days | 10 (2–44) | 4 (1–27) | 0.007 | Significant reduction in duration of ventilation |
Q: Why might steroids be beneficial in treating pneumonia?
A: Steroids may help control an excessive inflammatory response associated with infection, which can contribute to disease severity and complications in pneumonia.
Q: What are the main side effects of steroids in pneumonia treatment?
A: Major side effects include hyperglycemia, GI bleeding, increased risk of infections, and neuropsychiatric symptoms.
Q: What did early RCTs (2005–2015) suggest about the impact of steroids on pneumonia outcomes?
A: Early RCTs showed mixed results:
Q: What were limitations of early RCTs on steroids in pneumonia?
A: Limitations included small sample sizes, varied inclusion/exclusion criteria, differences in steroid types and dosing protocols, and potential inclusion of patients with pneumonia mimics.
Q: What did meta-analyses reveal about steroid benefits in pneumonia?
A: Meta-analyses suggested that steroids may reduce mortality in severe CAP (community-acquired pneumonia), reduce mechanical ventilation need, shorten ICU stays, and increase clinical stability time. However, steroids consistently increased hyperglycemia.
Q: Are there different guidelines regarding steroids in pneumonia?
A: Yes, the European guidelines (ESICM/SCCM) recommend steroids for severe CAP, while the American (ATS/IDSA) guidelines recommend against them, reflecting ongoing debate.
Q: What was the main question of the CAPE COD trial?
A: The CAPE COD trial asked if IV hydrocortisone reduces mortality in patients hospitalized with severe CAP.
Q: What were the results of the CAPE COD trial?
A: The trial found:
Q: Why did the CAPE COD trial show a larger benefit with steroids?
A: Possible reasons include:
Q: In which patients with pneumonia might steroids be most beneficial?
A: Steroids appear to benefit patients with severe pneumonia, especially those with high levels of inflammation (e.g., elevated CRP).
Q: What questions remain about the best way to use steroids in CAP?
A: Unanswered questions include:
Q: What is the clinical recommendation regarding steroids in CAP?
A: Clinicians should carefully select patients with severe CAP for steroid treatment, considering the mixed evidence and the potential for side effects like hyperglycemia.